Share Price | Ganga Pharmaceuticals Ltd Stock Analysis & Recommendation

Q: Who are the top shareholders of the Ganga Pharma.?

The top shareholders of Ganga Pharma include the promoters, with Sharma Bharat B holding the largest share at 30.12%. The highest public shareholder is Lenus Finvest Private Limited, which owns 7.75%. Additionally, individual investors collectively hold 35.07% of the company's shares. There are currently no mutual funds or foreign institutional investors (FIIs) holding shares in the company.

Q: How has been the historical performance of Ganga Pharma.?

Answer:The historical performance of Ganga Pharma shows a consistent trend in its financial metrics over the years.Breakdown:Ganga Pharma's share capital remained stable at Rs 4.84 crore from March 2024 to March 2025, while total reserves increased slightly from Rs 1.59 crore in March 2024 to Rs 1.67 crore in March 2025. Shareholder's funds also saw a modest rise, reaching Rs 7.13 crore in March 2025, up from Rs 7.05 crore the previous year. Long-term borrowings decreased from Rs 0.39 crore in March 2024 to Rs 0.23 crore in March 2025, indicating a reduction in debt levels. Total liabilities increased to Rs 8.97 crore in March 2025 from Rs 8.65 crore in March 2024, while total assets also rose to Rs 8.97 crore in March 2025 from Rs 8.65 crore in March 2024. The book value per share adjusted slightly to Rs 13.46 in March 2025 from Rs 13.30 in March 2024. Cash flow from operating activities remained at zero across the years, with cash flow from investing activities showing a positive inflow of Rs 1 crore in March 2025, contrasting with no activity in the previous year. Overall, Ganga Pharma's financial position reflects stability with slight improvements in reserves and assets, while maintaining low debt levels.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

8.0 k (400.00%) Volume

Shareholding (Mar 2026)

FII

0.00%

Held by 0 FIIs

DII

0.00%

Held by 0 DIIs

Promoter

50.91%

Who are the top shareholders of the Ganga Pharma.?

28-Apr-2025

The top shareholders of Ganga Pharma include Sharma Bharat B with 30.12%, Lenus Finvest Private Limited at 7.75%, and individual investors holding 35.07%. There are no mutual funds or foreign institutional investors currently involved.

View full answer

Who are in the management team of Ganga Pharma.?

28-Apr-2025

As of Mar 2023 The management team of Ganga Pharma includes Sanjay Vyankatesh Kulkarni (Chairman), Bharat Brijmohan Sharma (Managing Director & CEO), Srijna Sharma (Whole-time Director), and independent directors Sachin Chandrakant Chavan and Chetan Bhikhubhai Patel. They oversee the company's operations and strategic direction.

View full answer

Has Ganga Pharma. declared dividend?

30-Apr-2025

No Dividend History Available

How big is Ganga Pharma.?

24-Jul-2025

As of 22nd July, Ganga Pharmaceuticals Ltd has a market capitalization of 6.00 Cr, with Net Sales of 5.49 Cr and a Net Profit of 0.16 Cr reported in the latest four quarters. The company has Shareholder's Funds of 7.05 Cr and Total Assets of 8.65 Cr as of March 2024.

View full answer

How has been the historical performance of Ganga Pharma.?

09-Nov-2025

Ganga Pharma's historical performance shows stable share capital and a slight increase in reserves and shareholder's funds, with reduced long-term borrowings and improved total assets. Overall, the company reflects financial stability with low debt levels and positive cash flow from investing activities.

View full answer

When is the next results date for Ganga Pharmaceuticals Ltd?

15-May-2026

The next results date for Ganga Pharmaceuticals Ltd is 21 May 2026.

View full answer

Why is Ganga Pharmaceuticals Ltd falling/rising?

03-Jun-2026

As of 02-Jun, Ganga Pharmaceuticals Ltd's stock price is stable at 12.00 with no change, outperforming the Sensex which has declined. Year-to-date, it has increased by 2.74%, indicating resilience despite a 9.91% decline over the past year.

View full answer

Which are the latest news on Ganga Pharma.?

03-Jun-2026

When is the next results date for Ganga Pharmaceuticals Ltd?

Compare Ganga Pharma. with Similar Stocks

Vivanza Biosci.Brawn Biotech Decipher Labs

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Loading Valuation Snapshot...

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

INR 7 Cr (Micro Cap)

P/E

89.00

Industry P/E

Dividend Yield

0.00%

Debt Equity

0.19

Return on Equity

0.97%

Price to Book

0.86

Revenue and Profits:

Net Sales:

1 Cr

(Quarterly Results - Sep 2024)

Net Profit:

0 Cr

Total Returns

Total Returns (Price + Dividend)

Dividend Yield (0%)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

0.0%

6 Months

2.74%

1 Year

-9.91%

2 Years

-51.36%

3 Years

-13.85%

4 Years

16.85%

5 Years

0.0%

Ganga Pharma. for the last several years.

Risk Adjusted Returns v/s

Returns Beta

Beta has not been calculated since enough price history is not available

News & Corporate Actions

News

When is the next results date for Ganga Pharmaceuticals Ltd?

The next results date for Ganga Pharmaceuticals Ltd is scheduled for 21 May 2026....

Read full news article

Announcements

Compliances-Reg.24(A)-Annual Secretarial Compliance

28-May-2026 | Source : BSE

Non-Applicability of Annual Secretarial Compliance Report for the Financial Year ended March 31 2026

Audited Financial Results Of The Company For The Half Year And Financial Year Ended March 31 2026.

21-May-2026 | Source : BSE

Audited Financial Results of the Company for the half yeaar and financial year ended March 31 2026

Board Meeting Outcome for Outcome Of The Board Meeting Held On May 21 2026

21-May-2026 | Source : BSE

Outcome of the Board Meeting held on May 21 2026

Corporate Actions

BOARD MEETING

No Upcoming Board Meetings

DIVIDEND

No Dividend history available

SPLITS

No Splits history available

BONUS

No Bonus history available

RIGHTS

No Rights history available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

3.60%

EBIT Growth (5y)

0.40%

EBIT to Interest (avg)

-0.04

Debt to EBITDA (avg)

1.22

Net Debt to Equity (avg)

0.19

Sales to Capital Employed (avg)

0.38

Tax Ratio

23.08%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

ROCE (avg)

2.31%

ROE (avg)

0.99%

Valuation key factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

0.86

EV to EBIT

-8.63

EV to EBITDA

-8.63

EV to Capital Employed

0.88

EV to Sales

3.27

PEG Ratio

2.87

Dividend Yield

ROCE (Latest)

-1.63%

ROE (Latest)

0.97%

Technicals key factors

Indicator

Weekly

Monthly

Technical indicator has not been calculated since the stock has been active for a short period

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Mar 2026

Shareholding Compare (%holding)

Majority shareholders

Promoters

Pledged Promoter Holdings

None

Mutual Funds

Held by 0 Schemes

FIIs

Held by 0 FIIs

Promoter with highest holding

Sharma Bharat B (24.64%)

Highest Public shareholder

Bhavesh Dhirajlal Tanna (6.61%)

Individual Investors Holdings

35.32%

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Standalone) - Sep'24 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "Not Applicable: The company has declared_date for only one period",
        "dir": 0
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": "Not Applicable: The company has declared_date for only one period",
        "dir": 0
      }
    ],
    "table": {
      "header": [
        "Sep'24",
        "",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "1.31",
          "val2": "NA",
          "chgp": "NA",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-0.12",
          "val2": "NA",
          "chgp": "NA",
          "chgp_class": "neutral"
        },
        {
          "field": "Interest",
          "val1": "0.09",
          "val2": "NA",
          "chgp": "NA",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "NA",
          "chgp": "NA",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "0.02",
          "val2": "NA",
          "chgp": "NA",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-9.16%",
          "val2": "NA%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "half-yearly",
    "btn_text": "All Half Yearly Results",
    "header": "Half Yearly Results Snapshot (Standalone) - Sep'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": " Growth in half year ended Sep 2025 is 3.01% vs 1.53% in Mar 2025",
        "dir": 1
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": " Growth in half year ended Sep 2025 is -66.67% vs 200.00% in Mar 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Sep'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "1.37",
          "val2": "1.33",
          "chgp": "3.01%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-0.01",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Interest",
          "val1": "0.07",
          "val2": "0.09",
          "chgp": "-22.22%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "0.02",
          "val2": "0.06",
          "chgp": "-66.67%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-0.73%",
          "val2": "0.00%",
          "chgp": "-0.73%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "nine-monthly",
    "btn_text": "All Nine Monthly Results",
    "header": "Nine Monthly Results Snapshot (Standalone) - Sep'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in nine months ended Sep 2024 is 1.90% vs -1.13% in Sep 2024",
        "dir": 1
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": "YoY Growth in nine months ended Sep 2024 is 0.00% vs -20.00% in Sep 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Sep'24",
        "Sep'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "2.68",
          "val2": "2.63",
          "chgp": "1.90%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-0.13",
          "val2": "-0.07",
          "chgp": "-85.71%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.16",
          "val2": "0.18",
          "chgp": "-11.11%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "0.04",
          "val2": "0.04",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-4.85%",
          "val2": "-2.66%",
          "chgp": "-2.19%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Standalone) - Mar'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Mar 2025 is -3.65% vs 5.79% in Mar 2024",
        "dir": -1
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": "YoY Growth in year ended Mar 2025 is 60.00% vs 25.00% in Mar 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Mar'25",
        "Mar'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "2.64",
          "val2": "2.74",
          "chgp": "-3.65%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-0.11",
          "val2": "0.06",
          "chgp": "-283.33%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.18",
          "val2": "0.18",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "0.08",
          "val2": "0.05",
          "chgp": "60.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-4.17%",
          "val2": "2.19%",
          "chgp": "-6.36%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Standalone) - Sep'24 - YoY

Sep'24

Change(%)

Net Sales

1.31

Operating Profit (PBDIT) excl Other Income

-0.12

Interest

0.09

Exceptional Items

0.00

Standalone Net Profit

0.02

Operating Profit Margin (Excl OI)

-9.16%

NA%

Values in Rs Cr.

Compare with Peers

Net Sales

Not Applicable: The company has declared_date for only one period

Standalone Net Profit

Not Applicable: The company has declared_date for only one period

All Quarterly Results

Half Yearly Results Snapshot (Standalone) - Sep'25

Sep'25

Mar'25

Change(%)

Net Sales

1.37

1.33

3.01%

Operating Profit (PBDIT) excl Other Income

-0.01

0.00

Interest

0.07

0.09

-22.22%

Exceptional Items

0.00

Standalone Net Profit

0.02

0.06

-66.67%

Operating Profit Margin (Excl OI)

-0.73%

0.00%

-0.73%

Values in Rs Cr.

Compare with Peers

Net Sales

Growth in half year ended Sep 2025 is 3.01% vs 1.53% in Mar 2025

Standalone Net Profit

Growth in half year ended Sep 2025 is -66.67% vs 200.00% in Mar 2025

All Half Yearly Results

Nine Monthly Results Snapshot (Standalone) - Sep'24

Sep'24

Change(%)

Net Sales

2.68

2.63

1.90%

Operating Profit (PBDIT) excl Other Income

-0.13

-0.07

-85.71%

Interest

0.16

0.18

-11.11%

Exceptional Items

0.00

Standalone Net Profit

0.04

Operating Profit Margin (Excl OI)

-4.85%

-2.66%

-2.19%

Values in Rs Cr.

Compare with Peers

Net Sales

YoY Growth in nine months ended Sep 2024 is 1.90% vs -1.13% in Sep 2024

Standalone Net Profit

YoY Growth in nine months ended Sep 2024 is 0.00% vs -20.00% in Sep 2024

All Nine Monthly Results

Annual Results Snapshot (Standalone) - Mar'25

Mar'25

Mar'24

Change(%)

Net Sales

2.64

2.74

-3.65%

Operating Profit (PBDIT) excl Other Income

-0.11

0.06

-283.33%

Interest

0.18

Exceptional Items

0.00

Standalone Net Profit

0.08

0.05

60.00%

Operating Profit Margin (Excl OI)

-4.17%

2.19%

-6.36%

Values in Rs Cr.

Compare with Peers

Net Sales

YoY Growth in year ended Mar 2025 is -3.65% vs 5.79% in Mar 2024

Standalone Net Profit

YoY Growth in year ended Mar 2025 is 60.00% vs 25.00% in Mar 2024

All Annual Results

Company CV

About Ganga Pharmaceuticals Ltd

Ganga Pharmaceuticals Ltd

Micro Cap

Pharmaceuticals & Biotechnology

Ganga Pharmaceuticals Limited was incorporated as a Public Limited Company in Aug.'94 and promoted by Brij Mohan Sharma. The Company is engaged in the business of manufacturing & trading in Pharmaceuticals & allied products (Ayurveda). In Apr.'95, the company took over Ganga pharmaceuticals, a proprietary concern (owned by the same promoter), which was manufacturing and marketing ayurvedic products since the last two decades.

Company Coordinates

Company Details

Gangatat Dhanvantri Marg, Gopcharpada Virar (E) Palghar Maharashtra : 401305

Tel: 91-250-6098333/444

http://www.ayurvedganga.com

ayurvedganga@gmail.com

Registrar Details

Karvy Computershare Pvt Ltd., Karvy Selenium, Tower-B Plot No 31 & 32, Survey No 116/22, 115/24, 115/25, Financial District, Nanakramguda, Serilingampally, Mandal Ranga Reddy Dist, Hyderabad